Aurobindo Pharma arm recalls 59k vials of antipsychotic Fluphenazine Decanoate injection from US

Aurobindo Pharma arm AuroMedics Pharma LLC is recalling 59,500 vials of the injection on account of "Discoloration; hazy solution found in one vial instead of a clear solution," the US Heath Regulator (USFDA) said in its latest Enforcement Report.

New Delhi: Aurobindo Pharma arm AuroMedics Pharma LLC is recalling 59.5 thousand vials of antipsychotic Fluphenazine Decanoate injection USP 125mg/5mL, (5 mL multiple dose vial) from the US market, the USFDA said.

Aurobindo Pharma arm AuroMedics Pharma LLC is recalling 59,500 vials of the injection on account of "Discoloration; hazy solution found in one vial instead of a clear solution," the US Heath Regulator (USFDA) said in its latest Enforcement Report.

The product was distributed to major wholesalers/distributors who may have further distributed the product throughout the US, it added.

The voluntary ongoing recall is a class II recall, the United States Food and Drug Administration (USFDA) said.

Read Also: Johnson and Johnson hit with whooping USD 8 billion verdict over antipsychotic drug Risperda

As per the regulator, class II recall is initiated in a "situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote".

Fluphenazine Decanoate Injection, USP is a long--acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (for example chronic schizophrenics).

Read Also: SETBACK: Correvio Pharma heart drug Brinavess fails to win USFDA panel backing